Venous thromboembolism after high-dose chemotherapy in a patient with Hodgkin's lymphoma receiving the new oral contraceptive ethinylestradiol and drospirenone ("Yasmine").
Tartarone
A
A
Gallucci
G
G
Cammarota
A
A
Romano
G
G
Ardito
R
R
Di Renzo
N
N
D000328:Adult; D000736:Androstenes / Q000009:adverse effects*; D000792:Angiography; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D002330:Carmustine / Q000627:therapeutic use; D003280:Contraceptives, Oral, Synthetic / Q000009:adverse effects; D003561:Cytarabine / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D019934:International Normalized Ratio; D008234:Lynestrenol / Q000009:adverse effects*; D008558:Melphalan / Q000627:therapeutic use; D000451:Mineralocorticoid Receptor Antagonists / Q000009:adverse effects; D012306:Risk; D012307:Risk Factors; D013997:Time Factors; D020246:Venous Thrombosis / Q000209:etiology*; D014859:Warfarin / Q000009:adverse effects
D000736:Androstenes; D003280:Contraceptives, Oral, Synthetic; D000451:Mineralocorticoid Receptor Antagonists; D003561:Cytarabine; D014859:Warfarin; D005047:Etoposide; C035144:drospirenone; D008234:Lynestrenol; D008558:Melphalan; D002330:Carmustine